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Abstract
Background: RRP is a devastating disease in which papillomas in the airway cause hoarseness and breathing difficulty. The
disease is caused by human papillomavirus (HPV) 6 or 11 and is very variable. Patients undergo multiple surgeries to
maintain a patent airway and in order to communicate vocally. Several small studies have been published in which most
have noted that HPV 11 is associated with a more aggressive course.
Methodology/Principal Findings: Papilloma biopsies were taken from patients undergoing surgical treatment of RRP and
were subjected to HPV typing. 118 patients with juvenile-onset RRP with at least 1 year of clinical data and infected with a
single HPV type were analyzed. HPV 11 was encountered in 40% of the patients. By our definition, most of the patients in
the sample (81%) had run an aggressive course. The odds of a patient with HPV 11 running an aggressive course were 3.9
times higher than that of patients with HPV 6 (Fisher’s exact p=0.017). However, clinical course was more closely associated
with age of the patient (at diagnosis and at the time of the current surgery) than with HPV type. Patients with HPV 11 were
diagnosed at a younger age (2.4y) than were those with HPV 6 (3.4y) (p=0.014). Both by multiple linear regression and by
multiple logistic regression HPV type was only weakly associated with metrics of disease course when simultaneously
accounting for age.
Conclusions/Significance Abstract: The course of RRP is variable and a quarter of the variability can be accounted for by
the age of the patient. HPV 11 is more closely associated with a younger age at diagnosis than it is associated with an
aggressive clinical course. These data suggest that there are factors other than HPV type and age of the patient that
determine disease course.
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Introduction
It is now well established that human papilloma virus (HPV)
causes recurrent respiratory papillomatosis (HPV) [1]. The most
common types associated with the vast majority of RRP are HPV
6 and 11[2,3]. While millions of children and adults are exposed,
relatively few develop clinical evidence of the disease. The age of
disease onset is highly variable and so is the clinical course [4]. The
spectrum from indolent to aggressive is very wide. While the
presence of HPV is necessary to develop RRP it is not sufficient by
itself. We have previously postulated that genetically encoded host
susceptibility plays a role in whether or not an individual develops
RRP[5] and have started investigating epidermodysplasia verruciformis
1 (EVER1) as a candidate gene [6]. The current study explores the
other side of the host-pathogen interaction. Apart from host
genetic factors, genetic variability intrinsic to viral genomes could
also play a role in defining the clinical course of RRP. Previous
studies have examined the relationship between HPV types and
clinical disease behavior but the findings have not been
consistently replicable. For example, the vast majority of previous
studies have reported that human subjects infected with HPV 11
are more likely to develop an aggressive course of RRP compared
to those infected with HPV 6 [7–13]. However, one study [14]
revealed that HPV 6, not HPV 11, was more prevalent in children
PLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2263with aggressive RRP. Similar findings were reported with HPV 6
subtype C [15] (later shown to be HPV 11), and two studies
reported no association between HPV type and clinical course
[16–17].
As of April 2007, we have collected fresh, laryngeal biopsies
from over 130 unique patients with RRP in collaboration with the
RRP Task Force. To our knowledge, this collection of specimens
represents the largest of its type in the world. The current study
brings the largest dataset yet developed to bear on the potential
relationship between clinical course and HPV type. Equally
importantly, and often neglected, we explore how much of the
variability of the disease can be attributed to the type of HPV
while simultaneously accounting for other variables such as age.
Results
Between January 2003 and April 2007 fresh papilloma biopsies
were preserved in TRIzolH from 135 unique patients with RRP
and were subjected to HPV typing. By using both allele specific
PCR and RFLP typing on all cases we were able determine
whether HPV 6 versus HPV 11 was present in the papilloma.
Papillomas from 8 cases were positive for both HPV 6 and HPV
11 by both methodologies. Thus data was available on 127 unique
patients who either had HPV 6 or HPV 11. Eight of the cases were
excluded since we had less than one year of clinical course data
(HPV 6=7, HPV 11=1, median age=6.8y). Of the remaining
119 unique cases only one had adult-onset RRP and therefore was
excluded. (Table 1)
Initial analysis was directed at determining whether or not HPV
type and clinical course were associated or independent of each
other. There was indeed an association between HPV 11 and a
more aggressive course (Table 2). ‘‘Aggressiveness’’ was a label
based on a composite of four separate criteria. The labeling, also
called coding, was decided upon before subjects were enrolled in
the study. The four individual criteria making up the composite
label are defined in the methods section: total number of surgeries,
frequency of surgery, distal involvement, tracheostomy status. Not
only did we analyze the composite clinical course as a function of
the HPV type but we also sought an association between HPV
type and each separate criteria (Table 3). The odds ratio for total
number of procedures was 2.6 (95% CI 1.0 to 7.5) for subjects with
HPV 11 as opposed to those with HPV 6, for maximum annual
frequency it was 2.0 (95% CI 0.86 to 4.9), for tracheostomy status
it was 3.4 (95% CI 0.84 to 16) and for distal involvement the odds
ratio was 3.7 (95% CI 1.4 to 9.8) with 40% of the HPV 11 cases
having had distal involvement as opposed to 15% of HPV 6 cases.
Distal involvement frequently portends a severe clinical course but
none more so than that subgroup which has pulmonary
involvement. In the sample of 118 cases, 6 had pulmonary
involvement. Three of the 6 cases were infected with HPV 6 and
the other 3 had HPV 11. We did not specifically collect data
regarding malignant transformation but no such information was
volunteered on the data collection forms for the 118 patients.
Rather than simply looking at the data dichotomously
(aggressive vs. indolent) the total number of surgeries were
analyzed as a count variable. Total number of surgeries thus far
in the clinical course was log transformed since the untransformed
variables were highly skewed. The geometric mean number of
surgeries in the cases with HPV 6 was 16 and in the cases with
HPV 11 it was 30 (t-test p-value=0.005) suggesting that subjects
infected with HPV 11 tend to follow an aggressive course of the
disease.
The above data not only represents yet another set supporting
the association between HPV 11 and aggressive course but it is
also the largest data set to ever be analyzed. At this point one may
conclude the case finally settled and resolve to use HPV typing as a
clinical prognosticator. Yet that would be premature since other
variables, and not just HPV type may be associated with clinical
course.
Table 1. Data pertaining to 118 patients with RRP were subjected to further analysis.
Gender male=68 (58%), female=50 (42%)
Race White=67 (57%), Black=41 (35%), Asian, Other or Not Recorded=10 (8%)
Hispanic ethnicity Hispanic=11 (9%), Non-Hispanic=107 (91%)
Age at diagnosis median=3.0 years, range=(0.1, 13.1)
Duration of follow up (years) median=5.2 years, range=(0.9, 33)
Total number of surgeries median=19, range=(2, 402)
Max number of surgeries in a 12 month period median=4, range=(1, 52)
Interval since previous surgery median=113 days, range=(10 days, 3 years)
Distal Involvement involved=30 (25%), uninvolved=88 (75%)
Tracheostomy currently or previously=12 (10%), never=106 (90%)
Aggressiveness of course aggressive=95 (81%), indolent=23 (19%)
HPV type HPV 6=71 (60%), HPV 11=47 (40%)
Subjects who had both HPV 6 and 11 present and subjects for whom there was less than 1 year of clinical data were excluded. The descriptive statistics are stated.
doi:10.1371/journal.pone.0002263.t001
Table 2. Contingency table of HPV type versus nature of
clinical course.
indolent Aggressive
odds ratio
(p-value)
HPV 6 19 52 (73% of all HPV 6 cases)
HPV 11 4 43 (91% of all HPV 11 cases) 3.9 (0.02)
Fisher’s exact test yielded a p-value of 0.017 with odds ratio of 3.9 (95% CI 1.2 to
17) and a risk difference of 28%. A clinical course was defined as ‘‘aggressive’’ if
any of the following criteria were met: total procedures $10, procedure
frequency ever $4 per year, ever had distal involvement, ever had a
tracheostomy tube.
doi:10.1371/journal.pone.0002263.t002
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Yet there was no association between them and disease course.
Age can be cut into a dichotomous variable but with no obvious
cut point. The variable fitted a Gaussian distribution best when it
was transformed by taking the square root. Thus the mean age at
the time of diagnosis of the children who had experienced an
aggressive course was 2.7 years, but was 4.3 years for those with an
indolent course (t-test p-value=0.01). For the 6 cases with
pulmonary involvement, the mean age of diagnosis(based upon
square root transformed data) was 1.3 years for those affected and
3.1 years for those with no recorded pulmonary involvement (t-test
p-value=0.002). The range of age of diagnosis for those with
pulmonary involvement was 0.5 to 2.6 years. In other words, all 6
cases fell below the 42nd percentile for the sample as a whole.
While age of diagnosis has been associated with aggressiveness as
measured by the frequency of surgery, Reeves et al. [18]
demonstrated quite clearly that surgical frequency was more a
function of the age of the child at the time that the frequency is
being measured, than the age of the child at the time of diagnosis.
Our data collection method differed from that of Reeves et al. and
therefore the current analysis investigated the frequency by
looking at the number of days since the surgery prior to the
surgery at which the patient’s papilloma biopsy was taken. As
Reeves et al. found, there was indeed a correlation between the
age at enrollment and the interval since the last surgery. Linear
regression revealed that 20% of the variability in the interval since
the last surgery was a function of the age at enrollment
(p=4*10
27). On the other hand, HPV type was not related to
the interval since the last surgery (t-test p-value=0.25). (Figure 1)
It is quite conceivable that the duration between any two
surgeries may be a function of more than just the current
aggressiveness of the disease. Some surgeons schedule subsequent
surgery as symptoms dictate, whereas other surgeons set a pre-
determined duration based upon the agressiveness of the clinical
course over the preceding year. Others have adopted a hybrid of
the two methods. The variation in practice style was controlled for
by coding the surgeon’s response for each patient as 1 for ‘‘as
required (prn)’’, 2 for ‘‘hybrid’’ and 3 for ‘‘predetermined’’.
Adding the surgeon’s style to the linear model accounted for an
additional 7% of the variability (p-value=0.010). Age at diagnosis
was added to the model and further accounted for some of the
variability in a statistically significant manner (p-value=0.014)
albeit that it only accounted for 6% of the variability. So while age
at diagnosis was correlated with the duration since the preceding
surgery, this correlation was very weak when contrasted against
that of age at the time of enrollment in the study. Together, age at
enrollment+age at diagnosis+surgeon’s style of determining
surgical interval accounted for 31% of the variability in the time
since the preceding surgery. Adding HPV type accounted for none
of the residual variability. Thus in the multiple linear regression
equation where y=log (days between last and second last surgery),
coefficients were calculated for 4 variables simultaneously; in other
words it was not a step-wise hierarchical model where a
subsequent term is allowed to explain the residual left over after
a preceding term has already been entered into the model. The p-
values for each of the estimated coefficients were as follows: HPV
type=0.95, square root of at age of enrollment=6610
25, square
root of age at diagnosis=0.015 and surgeon’s style=0.013.
Fourteen observations were excluded either because the surgeon’s
style was missing or the patient had been enrolled at the time of
the first surgical intervention and thus there was no duration
between the last and the second last surgery. Similarly, mother’s
highest educational qualification and gross household income
accounted for none of the variability. Even the anatomical
component of the Derkay/Coltrera score at the time of enrollment
did not account for the variability in the time since the last surgery
given that the age variables and the surgeon’s style had already
been accounted for.
Since the duration between surgery at the time of enrollment in
the study and the preceding surgery utilizes information from only
a small interval of the subject’s clinical course it may be highly
variable. Thus, a similar analysis was conducted using the annual
frequency of surgeries around the time of the enrollment. The
sampling period was a median of 1.8 years (range 0.9 to 2). As
above, the age was transformed to the square root and the
frequency of procedures in the time period surrounding enroll-
ment was log transformed. Results were similar to that obtained
above; a simple linear regression model declared that square root
of the age at the time of enrollment accounted for 20% of the
variability in the natural log of the annual frequency of surgeries
around the time of enrollment (p=4.6*10
27). Together, age at
enrollment+age at diagnosis+surgeon’s style of determining
surgical interval accounted for 37% of the variability in the time
since the preceding surgery. However, unlike for the variability in
Table 3. Contingency table of HPV type versus four individual criteria that taken together constituted the composite
‘‘aggressiveness’’ label.
Surgery Count total procedures ,10
total procedures $10
(row percentage)
odds ratio (p-value by
Fisher Test)
HPV 6 25 46 (64% of all HPV 6 cases)
HPV 11 8 39 (83% of all HPV 11 cases) 2.6 (0.04)
Max Surgery Frequency procedure frequency never $4 per year procedure frequency ever $4 per year
HPV 6 31 40 (56%)
HPV 11 13 34 (72%) 2.0 (0.08)
Distal Involvement distal involvement: never has had distal involvement
HPV 6 60 11 (15%)
HPV 11 28 19 (40%) 3.7 (0.004)
Tracheostomy tracheostomy: never has had tracheostomy
HPV 6 67 4 (6%)
HPV 11 39 8 (17%) 3.4 (0.06)
doi:10.1371/journal.pone.0002263.t003
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very highly significantly correlated with both age variables: age at
time of measuring frequency p-value=0.00023; age at time of
diagnosis p-value=0.00020. Adding HPV type once again
accounted for none of the residual variability.
We have seen above that HPV 11 is associated with a more
aggressive clinical course as is young age of the patient, with clinical
course being far more correlated with age than with HPV type. In
fact HPV type is correlated with age of the patient and this is why
one sees an association between HPV type and clinical course, if not
simultaneously controlling for the age of the patient. This is most
easily seen if one performs logistic regression with clinical course
measured as a binomial variable as defined above. Children with
HPV 11-induced disease are diagnosed at a younger age than
children with HPV 6; the average age of diagnosis amongst those
with HPV 6 was 3.4 years and the average age of diagnosis for those
with HPV 11 was 2.4 years (t test p-value=0.014). Logistic
regression in which HPV-type was stipulated as the sole
independent variable accounted for 5.6% of the deviance (p-
value=0.02)and when age ofdiagnosis (transformed to square root)
was the sole independent variable, it accounted for 7.4% of the
deviance (p-value=0.005). When the two variables were handled
simultaneously in a multiple logistic regression then 12% of the
deviance was accountedfor with the individualp-values being 0.057
for HPV Type and 0.017 for age of diagnosis.
Discussion
RRPis a devastating disease-sometimes because of the urgency of
symptoms at presentation (such as respiratory distress), but far more
commonlybecauseofthechronicityofthediseaseandthemultitude
of surgeries undertaken. Amongst the many patients with RRP
there is considerable variability in the clinical course. For many
years investigators have explored the relationship between the
clinical course, and whether the patient was infected by HPV type 6
or type 11, but many studies suffered from small sample size. Now,
thanks to a large multi-center collaboration that was founded to
explore the underlyinggenetic susceptibility to RRP, we haveaccess
to the largest dataset ever assembled. With confidence one can note
that HPV 11 is associated with a more aggressive disease but that
the clinical course is more closely associated with the age of the child
which in turn is associated with HPV type.
Younger children tend to have a more aggressive clinical course
and so do children with HPV 11. However, HPV type is
associated with both the age of the child and with the outcome,
namely an aggressive clinical course. Once the age of the child is
Figure 1. Papilloma biopsies were taken at the time of enrollment and subjected to HPV typing. For those cases where the enrollment
surgery was not their first surgery, the interval in days since the last surgery was recorded. Variables were transformed so that they would comply
with a Gaussian distribution. The natural log of the number of days since the last surgery are depicted on the y axis. The left panel depicts a linear
regression against the square root of the age at the time of enrollment. The model predicts that a 4 year old last had surgery 69 days (2.3 months)
ago and a 9 year old last had surgery 113 days (3.7 months) but only 20% of the variability is accounted for by this model. The right panel depicts a
boxplot of the same data but clustered by HPV type. The geometric mean of the number of days since the last surgery was 119 days (3.9 months) for
those with HPV 6 and a similar 97 days (3.2 months) for those with HPV 11. The t-test p-value was 0.25.
doi:10.1371/journal.pone.0002263.g001
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clinical course becomes one of borderline significance. We can
speculate upon the association between the age of the child and
frequency of surgery. Investigators have believed that the
relationship is due to the relatively small airway of younger
children demanding more frequent surgery to keep it clear. In our
study we did not measure the diameter of the airway following
papilloma removal. The closest approximation to such a value can
be garnered from an article in which appropriate endotracheal
tube diameter was discussed for each age [19]. Such measure-
ments probably reflect the diameter of the subglottis. In our data
the estimated size of the airway did not account for the variability
in annual frequency once age was already in the model. Others
have speculated that the developing immune system may permit
older children to have slower papilloma growth. Although HPV 11
does not appear to be more virulent with respect to the clinical
course, the fact that it does affect those who are diagnosed at a
younger age may be a sign of virulence in and of itself. Since the
exposure for all cases was at the time of birth, the data herein
demonstrates that the incubation period for HPV 11 (2.4y) is
significantly shorter than for HPV 6 (3.4y).
Previous studies [18] have also shown that the age of the patient is
associated with the clinical course. The data collected by the RRP
Task Force in collaboration with the Centers for Disease Control
and Prevention was extensive. Given that RRP is a rare disease it
was a feat to have collected the data of 603 unique cases. A thorough
analysis of the data demonstrated the association with age quite
convincingly. The study was based on a medical record review and
since papilloma specimens were not obtained, HPV type was
unknown. Similarly, Silverberg et al. [4] also noted more frequent
surgeryinyoungerchildrenandnotedthatmostchildren(twothirds)
underwent less frequent surgery over time. Only 14% of the 42
children underwent more frequent surgery in later years than that
following diagnosis. Neither Reeves et al. nor Silverberg et al. could
comment on HPV type, but other studies have shown that younger
children seem to be more frequently infected by HPV 11 [10].
Multiple regression, be it linear or logistic, provides a way to explore
the three-way relationship of clinical course, age and HPV type.
A possible criticism of our findings is that we have analyzed a
biased sample of aggressive RRP cases based upon our acquisition
process. The data described herein was acquired for the principal
purpose of determining the underlying genetic susceptibility to
RRP. The design is cross-sectional and acquires probands at any
stage of their disease. Our enrollment mechanism was unlikely to
reach cases diagnosed a long time ago who subsequently had an
indolent course and went into remission before our study was
initiated. On the contrary those who were diagnosed at a similar
time but have endured an aggressive and protracted course would
have been reached by our acquisition mechanism. Furthermore,
we excluded 8 cases from analysis since the duration of their follow
up had been shorter than a year. These factors combined, bias our
sample to a generally more aggressive clinical course than the
population of all incident cases tracked over their lifetime. Another
weakness of this cross-sectional study is that data was not collected
from each and every surgical intervention. Rather, physical
findings were recorded only at the time of enrollment and
summary data pertaining to history were recorded at enrollment
and 1 year later. An ideal metric of papilloma burden would have
been a documentation of the full Derkay/Coltrera Staging Score
for each individual from the time of diagnosis to the time of
remission. The area under such a curve would be less subject to
stochastic phenomena in each individual’s course.
Less than half of RRP surgeons send papillomas for HPV typing
[20]. It is common for laboratories to only differentiate ‘‘high risk’’
from ‘‘low risk’’ as if risk was being determined for cervical cancer.
In other words, routine laboratory testing will differentiate HPV
16 from HPV 6/11; only highly specialized laboratories or
research laboratories would differentiate HPV 6 from HPV 11.
The vast majority of cases in this study were managed by surgeons
who were unaware of the HPV type and thus those deciding when
to operate were blinded with respect to HPV type.
Given the variability of the clinical course it would be useful to
be able to predict when a particular child would require
subsequent surgery. The current study suggests that HPV type
would be of no or little utility in making this determination. Age of
the patient at the time and age of the patient at diagnosis would be
more accurate predictors but even with these factors taken into
effect we could only account for about one third of the variability.
Malignant transformation of RRP is a devastating but rare
complication that has been investigated by others. Malignancy was
not specifically addressed by the incumbent study. Nevertheless, it
is important for the reader to be aware that other groups have
investigated the features of malignant transformation and have
associated them with pulmonary involvement and with HPV 11
exclusively (that is no isolates of HPV 6 from malignant RRP
biopsies) [12,21].
The cohort described herein had a similar rate of co-infection
compared to that which has already appeared in the literature. In
the initial cohort of 135 cases (before exclusions for insufficient
clinical course data) for whom we had fresh papilloma specimens,
only 8 (6%) were deemed to harbor both HPV 6 and 11. Following
exclusion of cases with insufficient clinical course data there were
only 5 cases with co-infection; statistical analysis of such a small
group would be of questionable meaningfulness. Furthermore, one
would not know if both HPV types were leading to the phenotype
since it is conceivable that one of the types had caused the disease
and the other was merely present much in the same way that HPV
6 and 11 have been found in the mucosa of people without RRP.
Our method of typing used two methods on each specimen (allele-
specific PCR and RFLP). Co-infection rates between papers could
be difficult to interpret since methodologies vary from study to
study. (Table 4)
Table 4. Listing of literature in which HPV typing was
reported.
Study HPV 6 HPV 11 coinfection
Rabah 2001[10] 29 (48%) 32 (52%) 0 (0%)
Wiatrak 2004 [11] 31 (53%) 23 (40%) 4 (7%)
Gabbott 1997 [16] 19 (43%) 24 (55%) 1 (2%)
Pou 1995 [8] 21 (88%) 2 (8%) 0 (0%)
Draganov 2006 [13] 6 (26%) 14 (61%) 3 (13%)
Padayachee 1993[14] 5 (25%) 15 (75%) 0 (0%)
Rimell 1997 [9] 9 (47%) 6 (36%) 4 (21%)
Szeps 2005 [28] 12 (66%) 6 (33%) 0 (0%)
Maloney 2006[29] 4 (27%) 4 (27%) 7 (47%)
Pou 2004 [30] 6 (46%) 7 (54%) 0 (0%)
Total 142 (48%) 133 (45%) 19 (6%)
Studies where co-infection rate could not be ascertained are not included
below. Articles are listed in descending order of sample size. The row entitled
‘‘Total’’ assumes that there was no overlap in the cohorts described. Some
studies noted other HPV types (such as HPV 16 in someone who had
undergone malignant transformation) and are not reported in this table.
doi:10.1371/journal.pone.0002263.t004
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Allegheny-Singer Research Institute in Pittsburgh, PA are
currently collaborating to determine the underlying genetic
susceptibility in RRP. A secondary objective is to determine what
the genetic factors are that account for the variability in clinical
course. One of the reasons for obtaining a papilloma specimen at
the time of enrollment was to determine whether the patient was
infected with HPV 6 or 11. We believed that HPV type would be
an important factor to control for in trying to observe an
association between aggressiveness and underlying genotype.
Given the data contained in this report it appears as if HPV type
may not be a significant variable, or if it is, then only weakly so.
While it is not known what factor(s) account for the remaining two
thirds of the variability in clinical course, a reasonable hypothesis
would be that host genetic factors account for the remainder of the
clinical variability. A genome wide search for those factors is
underway.
Methods
Sample composition
The RRP patients studied here were identified through an
ongoing collaborative study on the genetics of RRP with the
coordinating site located at Allegheny-Singer Research Institute,
Allegheny General Hospital, Pittsburgh, PA [5]. As of April 2007,
19 institutions have approved the study and thus far 15 have
contributed laryngeal specimens. People diagnosed with RRP and
managed by an otolaryngologist were invited to participate in the
study. At first the study was limited to pediatric patients and later
was opened to adult patients. The genetic susceptibility study has
two acquisition routes: satellite site design and patient-support
group design. In the satellite site design, cases were enrolled by
their attending otolaryngologist and laryngeal papilloma, blood
and clinical data were submitted. In the patient-support group
design, interested potential subjects contacted the principal
investigator. Arrangements were made for the subjects to submit
their clinical data and a ScopeH mouthwash specimen; no
papilloma specimens were obtained. Clearly, those subjects
enrolled through the patient-support group design could not be
included in the subset analyzed herein. The protocol was originally
approved by the institutional review board (IRB) of the Allegheny-
Singer Research Institute, Pittsburgh, PA. In an iterative process
the protocol was subsequently submitted to 20 separate IRBs over
a 5 year period and approval was obtained in the following order:
Children’s Hospital of the King’s Daughters, Norfolk, VA;
Children’s Hospital of Wisconsin, Milwaukee, WI; Children’s
National Medical Center, Washington, DC; Cincinnati Children’s
Hospital Medical Center, Cincinnati, OH, Johns Hopkins
Children’s Center, Baltimore, MD; Children’s Medical Center
of Dallas, Dallas, TX; Children’s Hospital of Philadelphia,
Philadelphia, PA; SUNY Upstate Medical Center, Syracuse,
NY; The Hospital for Sick Children, Toronto, ON, Canada;
Children’s Hospital of Alabama, Birmingham, AL; University of
California-San Francisco, San Francisco, CA; Children’s Hospital
of Pittsburgh, Pittsburgh, PA; Le Bonheur Children’s Medical
Center, Memphis, TN; Children’s Healthcare of Atlanta at
Egleston, Atlanta, GA; Bastian Voice Institute, Downers Grove,
IL; British Columbia’s Children’s Hospital, Vancouver, BC;
University of Mississippi Medical Center, Jackson, MS; Hospital
das Clı ´nicas da Faculdade de Medicina da Universidade de Sao
Paulo, Sao Paulo, Brazil; UPMC Presbyterian Hospital, Pitts-
burgh, PA; Yale-New Haven Children’s Hospital, New Haven,
CT. No IRB was prepared to engage in a cooperative review
agreement as allowed for in section 114 (45CFR46) the code of
federal regulations [22]. All human subjects or a parent (or legal
guardian) provided written informed consent. Written assent was
obtained from children in accordance with specific institutional
practice.
Clinical Course
Information about the clinical course of each case was supplied
by their otolaryngologist at the time of enrollment and one year
later updated clinical information was supplied. Metrics of clinical
course included total number of airway procedures (count),
frequency of procedures (count per year), ever had involvement
in the trachea or distally (binomial), ever had a tracheostomy
(binomial). A clinical course was defined as ‘‘aggressive’’ if any of
the following criteria were met: total procedures $10, procedure
frequency ever $4 per year, ever had distal involvement, ever had
a tracheostomy tube. If none of these criteria were met the patient
was considered to be experiencing an indolent course. Numeric
cuttoffs can appear arbitrary but the metrics used in this study are
based on precedence set by other investigator groups and
importantly, were decided upon a priori. Doyle et al, working in
New Orleans and Derkay, reporting a national survey of
otolaryngologists, used identical or similar cut offs for classifying
aggressive versus benign [23,24]. Their classification metrics have
been referred to by others and have been used by others [25,26].
For each patient the surgeon was asked about the manner in
which he or she decided to perform the next surgical intervention.
The exact wording on the forms was, ‘‘Some surgeons operate on
patients according to pre-determined intervals. Others only return
to the operating room on a prn (as required) basis. Some adopt a
hybrid approach whereby only the next interval is pre-determined
in response to what happened over the last one or two intervals.
What approach are you closest to with respect to this patient over
the past year? ‘‘The surgeon’s response for each patient was coded
as 1 for ‘‘as required (prn)’’, 2 for ‘‘hybrid’’ and 3 for ‘‘pre-
determined’’.
Specimen collection and DNA extraction
During surgery to control the patient’s disease, two 1mm by
1mm papilloma biopsies were collected by the patient’s attending
physician and preserved in 700 ml of TRIzolH solution contained
in a 1.5 ml microcentrifuge tube. The biopsy specimens were
shipped to Allegheny-Singer Research Institute, Pittsburgh, PA,
the specimen and data coordinating site. DNA was extracted from
laryngeal biopsies according to the manufacturer’s guidelines
(Invitrogen, Carlsbad, California). To assess the quantity and
quality of the isolated DNA, samples were tested by spectropho-
tometry using a ND-1000 spectrometer (NanoDrop) and by PCR
using the GH20 (59-GAAGAGCCAAGGACAGGTAC-39) and
PC04 (59-CAACTTCATCCACGTTCACC-39) primers which
span a 268 bp segment of the b-globin gene [27]. During the
early phase of establishing the specimen collection, several samples
failed to yield b-globin amplicons. Thus the specimens that failed
PCR were subjected to whole genome amplification (WGA) using
the GenomiPhi DNA Amplification Kit from Amersham Bio-
ciences (Piscataway, NJ) following the manufacturer’s instructions.
After the extraction of the first 45 laryngeal specimens, we decided
to systematically carry out WGA on all extracted DNA. The
products of the WGA reactions were tested by seeking the
presence of the 268 bp PCR fragment of the b-globin gene using
GH20 and PC04 primers.
HPV Typing
DNA was analyzed for the presence of HPV sequences by both
Type-Specific PCR primers (TS-PCR) and Restriction Fragment
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typing techniques were systematically used in our specimens to
ensure reproducibility and accuracy of genenotyping results. In
fact, like any other PCR-based genotyping, TS-PCR is very
sensitive and can produce either false positives or false negatives,
which is a potential explanation for the very high frequency of dual
infection reported in some RRP studies. RLFP typing using a
different set of PCR primers followed by specific endonuclease
digestion was used to replicate TS-PCR results and confirm HPV
genotype.
Type-Specific PCR
For each HPV type, two Type-Specific (TS) primers were
designed in the E6 (HPV 6) and L2 (HPV 11) region. Prior to
selecting the primers, HPV 6 and HPV 11 DNA sequences were
downloaded from the public database at Los Alamos National
Laboratory (http://hpv-web.lanl.gov/). These sequences were
aligned using BLAST 2 SEQUENCES (http://www.ncbi.nlm.
nih.gov/blast/bl2seq/wblast2.cgi) to reveal highly conserved and
discordant regions between the two types. Only areas of high DNA
sequence discordance were used to design primers using Oligo, a
primer analysis software V.6.65 (Molecular Biology Insights, Inc.,
Cascade, CO). The sequences of primers that best met Oligo PCR
primers design criteria and empirical annealing temperature were
as follow; HPV 6-specific primers: forward primer (6930) 59-
ACCTAAAGGTCCTGTTTCGAGG-39, reverse primer (6932)
59-CAGCGACCCTTCCACGTAC-39 and HPV 11: forward
primer(6931) 59-ATATACCCTTGGGAAGCTCTCC-39, re-
verse primer(6933) 59-TTGTTGGGGCAGATATAAGTATG-
39. These primers were blasted against public genomic databases
to ensure they matched to HPV 6 and 11 with high probability
scores. To empirically determine the optimal annealing temper-
ature for each primer set, a gradient PCR was then carried out
separately using each TS primer and HPV 6 and 11 cloned DNA
as template DNA (generously provided by Drs. P. Reidy and W.
Lancaster from Department of Otolaryngology, Wayne State
University, Detroit, MI). Annealing temperatures used were 67uC
and 68uC for both primers and AmpliTaq GoldH DNA
Polymerase from Applied Biosystems (Foster City, CA). HPV
positive and negative control reactions were included in all HPV
TS-genotyping experiments. The HPV-positive controls consisted
of HPV 6 and HPV 11 cloned genomic DNA. PCR products were
subjected to electrophoresis on 1% agarose gels, and visualized by
ethidium bromide staining (Figure 2).
Restriction Fragment Length Polymorphism (RLFP)
HPV6 and 11 consensus E7 and E1 primers Forward primer:
59-TGACCTGTTGCTGTGGATGT-39 and reverse primer 59-
GTGCATATAAACTTAATGGCTCAA-39 were used to amplify
a 929 bp DNA segment. PCR products were digested at 37uC
overnight using enzyme BstN I (New England Biolabs, Ipswich,
MA) following the manufacturer’s protocol. The products of the
digestion were run on 1% agarose gel and visualized by ethidium
bromide staining (Figure 3).
Statistical Analysis
Prior to any subject enrollment the primary metric of clinical
course was defined as the composite label ‘‘aggressive’’ or
‘‘indolent’’ as stated above under ‘‘clinical course’’. While clinical
course was considered a dependent outcome measure, the
following variables were considered to be independent potential
predictor variables: HPV type, age at diagnosis, age at enrollment,
gender, race, educational status of mother, gross household
income, surgeon’s style. The dataset was initially inspected by
conducting a descriptive statistical summary of all the variables in
isolation (R statistical software (http://www.r-project.org/)).
Boxplots and histograms of each variable were inspected. Several
Figure 2. Agarose gel electrophoresis of HPV 6 and 11 specific PCR fragments. The first 2 lanes after the ladder (both labeled ‘‘1’’) represent
the wells for HPV 6 positive control clone for the TS-PCR using either primer pair 6930–6932 (designed to be specific for HPV 6) or 6931–6933
(designed to be specific for HPV 11). The same pattern applies to the remaining lane couplets. The couplet labeled ‘‘2’’ represents HPV 11 positive
control clone. Couplets 3–8 are RRP specimens and couplet 9 is the PCR negative control. In this gel we see that that laryngeal DNA used in couplet 3
contained only HPV 11 and the remainder contained only HPV 6.
doi:10.1371/journal.pone.0002263.g002
Figure 3. HPV 6 and 11 genotyping by restriction fragment
length polymorphism. BstN I enzyme is a single cutter for the 929 bp
HPV6 and 11 consensus PCR fragment. HPV6 possesses the enzyme
recognition site thus the digestion yields two fragments of size 526 and
403 bp while HPV11 does not. Lanes 1 and 2 are HPV 6 and 11 positive
controls. Lanes 3–13 are RRP patients.
doi:10.1371/journal.pone.0002263.g003
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either transformed by taking the natural logarithm or by taking the
square root of the value. Age of diagnosis, age at enrollment, total
number of procedures, frequency of procedures per year, time
from last operation to time of current operation and gross
household income were transformed. Initial analysis consisted of
performing a Fisher exact test of independence for the two
binomial variables: HPV type (6 vs 11) and clinical course
(aggressive vs indolent). Secondarily, multiple logistic regression
was then used to analyze two independent variables that had been
repeatedly described in the literature; HPV type and the age of the
subject were simultaneously related to the dependent (outcome)
variable of clinical course (aggressive vs. indolent). Finally, in a
post-hoc manner, the 8 independent variables described above
were explored in models in which total number of surgeries,
frequency of surgery in a one year period and time between last
and second last surgery were modeled as continuous variables.
The purpose of the models was to determine the fraction of the
variability in the outcome that could be accounted for by the
known independent predictor variables. Specifically, we sought the
contribution of the HPV type in accounting for clinical course
variability in the context of other known variables. No adjustments
have been made for multiple testing.
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